Table 4.
Adjusted and unadjusted regression of 6-months EULAR response and patient-reported physical function*
| Logistic regression of EULAR responders vs. nonresponders | Ordinal regression of EULAR response | Logistic regression of achieving 0.22-unit improvement in HAQ score | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapy | Unadjusted | P | Adjusted† | P | Unadjusted | P | Adjusted† | P | Unadjusted | P | Adjusted‡ | P |
| Anti-TNF (reference) | ||||||||||||
| RTX | 1.35 (1.06, 1.71) | 0.01 | 1.31 (1.02, 1.69) | 0.04 | 1.34 (1.07, 1.68) | 0.01 | 1.34 (1.05, 1.70) | 0.02 | 1.48 (1.09, 2.01) | 0.01 | 1.49 (1.07, 2.08) | 0.02 |
*
Values are the odds ratio (95% confidence interval) unless indicated otherwise. EULAR = European League Against Rheumatism; HAQ = Health Assessment Questionnaire; anti-TNF = anti–tumor necrosis factor; RTX = rituximab.
†
Propensity score included Disease Activity Score in 28 joints, comorbidities, the failed anti-TNF therapy, and interaction between age and reason for switching.
‡
Propensity score included age, comorbidities, the last failed anti-TNF therapy, interaction between disease duration and the reason for switching, using the logistic regression propensity score model.